1. Assessed for eligibility (n=71)
Supplemental Figure 1.
Enrollment
Assessed for eligibility (n=71)
Randomized (n=71)
Allocation
Allocated to
Dapagliflozin (n=36)
Allocated to
Pioglitazone (n=35)
Follow-Up
No lost to follow up
Adverse events (n=2)
No lost to follow up
Adverse events (n=1)
Analysis
36 completed 24 week
follow-up observation
35 completed 24 week
follow-up observation

2. Supplemental Figure 2. ⊿Body weight (kg) ⊿Body weight (kg)
r = 0.16, p = 0.35
r = 0.43, p < 0.05
⊿HbA1c (%)
⊿HbA1c (%)
Dapagliflozin
Pioglitazone

3. Supplemental Figure 3. A B
⊿NT-proBNP (pg/mL)
⊿NT-proBNP (pg/mL)
r = , p < 0.01
r = , p < 0.05
Baseline log converted ACR
(log mg/g)
Baseline NT-proBNP (pg/mL)